Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Invests $1M in Calando Subsidiary

Premium

Arrowhead Research said this week that it has invested $1 million in its majority-owned subsidiary Calando Pharmaceuticals through the purchase of 60 million shares of preferred stock.

The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.

With the transactions, Arrowhead said it now holds about 79 percent of Calando's outstanding equity.